IGFBP7 and dexamethasone resistance in acute lymphoblastic leukemia
| Grant number: | 19/04943-3 |
| Support type: | Scholarships in Brazil - Doctorate |
| Effective date (Start): | June 01, 2019 |
| Effective date (End): | March 31, 2022 |
| Field of knowledge: | Biological Sciences - Genetics |
| Principal Investigator: | José Andrés Yunes |
| Grantee: | Leonardo Luís Artico |
| Home Institution: | Centro Infantil de Investigações Hematológicas Dr Domingos A Boldrini (CIB). Campinas , SP, Brazil |
Abstract Acute Lymphoblastic Leukemia (LLA) is the most common type of Cancer in childhood, accounting for about 30% of all Cancers and 80% of all leukemias occurring up to the age of 15 years. In the previous work, we verified that leukemic cells secrete several proteins, among them IGFBP7, which together with their ligands (insulin, IGF1 and IGF2) stimulate bone marrow stromal cells to produce asparagine, creating a contrary dynamic to the action of L-asparaginase (chemotherapy extensively used in ALL treatment). However, data recently submitted for publication show that IGFBP7 can act in an autocrine and stromal independent manner, contributing to the greater progression of ALL both in vitro and in vivo. In addition, preliminary results indicate that IGFBP7 protects ALL against cytostatic actions mediated by corticoid drugs, in order to antagonize the tumor suppressor activity of TGFb/p53 pathways, reducing nuclear translocation of the glucocorticoid receptor (GR). Based on preliminary results and the known relevance of the TGFb/p53 pathways for oncogenesis, we propose to characterize the interactions between the TGFb and the glucocorticoid receptor (GR) and their inhibition by IGFBP7 in ALL. More specifically, we intend to (1) confirm that IGFBP7 blocks the activation of the canonical pathway of TGFb/Smad and p53, mediated by TGFb1 and dexamethasone in ALL; (2) to characterize the physical interactions between GR/Smads and their modulation in response to stimuli with IGFBP7, TGFb1 and/or dexamethasone; (3) determining the physical ligands of IGFBP7 in ALL; and (4) to evaluate the therapeutic efficacy of anti-IGFBP7 antibody in mice transplanted with patient ALL xenograft and the synergistic effects mediated by dexamethasone. (AU) | |